Michael M. Allevato
Economics, Econometrics and Finance · University of Michigan
Publications
100
Citations
734
Est. group size
~1
Recurring co-author estimate
Active years
10
Publishing since 2017
Typically publishes in teams of ~15 · 1% small-team papers (≤3 authors) · across 15 venues
- Orthogonally targeted tumor radiosensitization using cell penetrating peptide-ATM inhibitor conjugates to stimulate anti-tumor immune responses
bioRxiv (Cold Spring Harbor Laboratory) · 2026
- Orthogonally targeted tumor radiosensitization using cell penetrating peptide-ATM inhibitor conjugates to stimulate anti-tumor immune responses
SSRN Electronic Journal · 2026
- Supplementary Figure 1 from Oncogenic HRAS Induces Metformin Resistance in Head and Neck Cancer by Promoting Glycolytic Metabolism
2026
- Supplementary Figure 5 from Oncogenic HRAS Induces Metformin Resistance in Head and Neck Cancer by Promoting Glycolytic Metabolism
2026
- Supplementary Figure 3 from Oncogenic HRAS Induces Metformin Resistance in Head and Neck Cancer by Promoting Glycolytic Metabolism
2026
- Supplementary Figure 4 from Oncogenic HRAS Induces Metformin Resistance in Head and Neck Cancer by Promoting Glycolytic Metabolism
2026
- Supplementary Figure 2 from Oncogenic HRAS Induces Metformin Resistance in Head and Neck Cancer by Promoting Glycolytic Metabolism
2026
- Orthogonally targeted tumor radiosensitization using cell penetrating peptide-ATM inhibitor conjugates to stimulate anti-tumor immune responses
Cancer Letters · 2026
- The tumor-sentinel lymph node immuno-migratome reveals CCR7⁺ dendritic cells drive response to sequenced immunoradiotherapy
Nature Communications · 2025
- Interactions of Antibody Drug Conjugate Anti‐Tubulin and Topoisomerase I Inhibitor Payloads with Radiotherapy to Potentiate Immunotherapy
Advanced Science · 2025
- Abstract P004: Mapping the tumor-sentinel node immune migratome demonstrates a key role for CCR7+ dendritic cells in the successful response to immunoradiotherapy
Clinical Cancer Research · 2025
- Abstract B019: Mapping the tumor-sentinel node immune migratome demonstrates a key role for CCR7+ dendritic cells in the successful response to immunoradiotherapy
Cancer Immunology Research · 2025
- Supplementary Figure 4 from A Kinome-Wide Synthetic Lethal CRISPR/Cas9 Screen Reveals That mTOR Inhibition Prevents Adaptive Resistance to CDK4/CDK6 Blockade in HNSCC
2025
- Supplementary Figure 1 from A Kinome-Wide Synthetic Lethal CRISPR/Cas9 Screen Reveals That mTOR Inhibition Prevents Adaptive Resistance to CDK4/CDK6 Blockade in HNSCC
2025
- Supplementary Tables 2 -5 from A Kinome-Wide Synthetic Lethal CRISPR/Cas9 Screen Reveals That mTOR Inhibition Prevents Adaptive Resistance to CDK4/CDK6 Blockade in HNSCC
2025
- Cancer Research×7
- Nature Communications×5
- bioRxiv (Cold Spring Harbor Laboratory)×4
- Cancer Letters×2
- Regular and Young Investigator Award Abstracts×2
- Michael E. Shepherd
Economics, Econometrics and Finance · University of Michigan
- Jiuling Yang
Medicine · University of Michigan
- Daniel Kupor
Medicine · University of Michigan
- Andrew J. Gunderson
Medicine · The Ohio State University
- Jianhui Gong
Medicine · University of Michigan
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 25, 2026.
Claim or correct this profile